CClinicalTrials.gg
CompletedNCT03816514Updated Dec 22, 2020

Noninvasive Hemoglobin Monitoring for Maintaining Hemoglobin Concentration Within the Target Range

An interventional study of SpHb monitoring and Conventional management in Hemoglobins, Blood Transfusion and Hemorrhage, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2020-12-22.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The primary aim of this study is to evaluate whether pulse oximetry based noninvasive hemoglobin (SpHb) monitoring can reduce the incidence of hemoglobin (Hb) level out of the target range in adult patients undergoing major surgery with the potential risk of bleeding.

02

Conditions studied

  • Hemoglobins
  • Blood Transfusion
  • Hemorrhage

Browse trials for

03

In context

Hemorrhage

3,000 studies on the registry are indexed under Hemorrhage; 474 are open to participants now.

This study's enrollment of 130 is above the median of 100 across 1,985 interventional studies indexed under Hemorrhage.

Browse Hemorrhage studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patients with ASA physical status class I, II, III, who scheduled to undergo elective non-cardiac major surgery with more than moderate risk of bleeding under general anesthesia or spinal anesthesia.
  • Eligible Surgery include: Spine surgery, bone tumor surgery, Total Hip Replacement, ovarian cancer surgery, cervical cancer surgery, radical cystectomy, open retroperitoneal mass excision, Radical Retropubic Prostatectomy, explorative laparotomy for abdominal mass excision, abdominal aortic aneurysm repair
  • Patients who are requiring an arterial catheter as a part of their standard care.

Exclusion criteria

Exclusion Criteria:

  • Patients with preexisting deformity or skin condition that would impede sensor placement
  • Patients with allergies to the adhesive sensor material
  • Patients with uncorrected preoperative anemia (preoperative hemoglobin \< 7 g/dL)
  • Patients who were not suitable for participation in the opinion of the study investigator.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    SpHb monitoring group

    In SpHb monitoring group, noninvasive, continuous SpHb monitoring will be done using Radical-7 pulse CO-Oximeter. The patients will be managed according to the prespecified protocol based on the SpHb values.

    Procedure: SpHb monitoring

  • Active comparator
    Control group

    In control group, patients will receive conventional management without the SpHb monitoring. In these patients, the information about hemoglobin concentration of the patients will be obtained from hemoglobin measurement analyzed by point-of-care (POC) equipment, as usual standard care.

    Procedure: Conventional management

Interventions

  • ProcedureSpHb monitoring

    Noninvasive, continuous pulse oximetry-based hemoglobin (SpHb) monitoring

  • ProcedureConventional management

    Conventional management without SpHb monitoring

06

What researchers measure

Primary outcomes

  1. The incidence of deviation from the target hemoglobin range

    (The number of laboratory samples with the result hemoglobin concentrations were out of the target range)/(Total number of laboratory samples that performed during intra-operative periods)

    Time frame: Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia

Secondary outcomes

  1. The percentage extent of deviation from the target hemoglobin range

    The percentage extent of deviation of laboratory hemoglobin out of the prespecified target range

    Time frame: Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia

  2. Number of Point-of-care (POC) sampling during surgery

    Number of Point-of-care (POC) sampling for measurement of hemoglobin concentration. In SpHb group, POC sampling will be done according to SpHb level. In control group, POC sampling will be done at discretion of anesthesiologist.

    Time frame: Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia

  3. Accuracy of the SpHb value

    Standard Laboratory hemoglobin measurement will be used as reference. Laboratory measurements will be done every 30 minute during surgery

    Time frame: Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia

  4. Number of patients who receive intra-operative transfusion

    Number of patients who were transfused with pRBCs intraoperatively

    Time frame: Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia

  5. Total volume of intravenous fluids given

    Total volume of intravenous fluids given intra-operatively

    Time frame: Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia

  6. Total volume of pRBCs transfused

    Total volume of pRBCs transfused intra-operatively

    Time frame: Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia

  7. Time for transfusion delay

    Time from the determination of transfusion to actual transfusion, in minutes

    Time frame: Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia

  8. Incidence of intraoperative hypotension

    hypotension is defined as SBP \< 80% of baseline SBP

    Time frame: Until transfer to PACU (Post-Anesthesia Care Unit), from the beginning of the induction of anesthesia

  9. laboratory total hemoglobin value, at postoperative day 1

    total hemoglobin value measured by standard laboratory method

    Time frame: at postoperative day 1

07

Study locations

1 site
  • Seoul national university hospital
    Seoul, 110-744, Korea, Republic of
08

References and documents

Publications

  • Berkow L, Rotolo S, Mirski E. Continuous noninvasive hemoglobin monitoring during complex spine surgery. Anesth Analg. 2011 Dec;113(6):1396-402. doi: 10.1213/ANE.0b013e318230b425. Epub 2011 Sep 29. PubMed 21965372 ↗
  • Causey MW, Miller S, Foster A, Beekley A, Zenger D, Martin M. Validation of noninvasive hemoglobin measurements using the Masimo Radical-7 SpHb Station. Am J Surg. 2011 May;201(5):592-8. doi: 10.1016/j.amjsurg.2011.01.020. PubMed 21545905 ↗
  • Galvagno SM Jr, Hu P, Yang S, Gao C, Hanna D, Shackelford S, Mackenzie C. Accuracy of continuous noninvasive hemoglobin monitoring for the prediction of blood transfusions in trauma patients. J Clin Monit Comput. 2015 Dec;29(6):815-21. doi: 10.1007/s10877-015-9671-1. Epub 2015 Mar 10. PubMed 25753142 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03816514
Lead sponsor
Seoul National University Hospital
Responsible party
Jin-Tae Kim (Professor, Seoul National University Hospital) — Principal investigator
First posted
Jan 25, 2019
Start date
Mar 4, 2019
Primary completion
Nov 2, 2020
Completion
Nov 6, 2020
Last update
Dec 22, 2020

Study contacts

Jin-Tae Kim, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion